Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer
Mené en Autriche et en Suède sur 3 425 patientes atteintes après la ménopause d'un cancer du sein HR+ de stade précoce, cet essai de phase III évalue l'intérêt, du point de vue de la durée avant l'apparition de fractures et de la survie sans maladie, et la toxicité d'un traitement adjuvant par dénosumab, dispensé pendant le traitement adjuvant par inhibiteurs d'aromatase (durée médiane de suivi : 73 mois)
During the past half a century, a series of progressive, large-scale, randomised controlled trials have incrementally and steadily improved survival for women with breast cancer. Notably, all of them have built on modest gains and, in many cases, it has taken well done meta-analyses to fully define the advantages of these treatments. Meta-analyses of multiple studies have convincingly shown that bisphosphonates reduce skeletal events, whether caused by loss of bone density or breast cancer involvement. These analyses have also shown a significant survival advantage with the addition of these agents.
The Lancet Oncology , commentaire, 2018